Combining osimertinib (Tagrisso) with the MET inhibitor savolitinib demonstrated encouraging antitumor activity and an acceptable safety profile in patients with EGFR-mutant, MET-amplified non–small cell lung cancer (NSCLC) who previously received EGFR TKIs, suggesting the regimen could be successful in overcoming MET-driven resistance. ...
